Market Place
Sourcing Support
The pharma& Group Partners With Tolmar to Promote Rubraca® for mCRPC
24 Sep 2024 //
PR NEWSWIRE
FDA sends CRL to Clovis in last-gasp bid for Rubraca nod
06 Jun 2023 //
FIERCE PHARMA
With Clovis in Chapter 11, Swiss firm buys up Rubraca for $70M
08 Apr 2023 //
FIERCE PHARMA
Clovis reveals even more regulatory troubles for Rubraca
13 Feb 2023 //
FIERCE PHARMA
Embattled Clovis Oncology Files for bankruptcy, Sells pipeline asset to Novartis
13 Dec 2022 //
BIOSPACE
Cancer drugmaker Clovis files for bankruptcy, hit by falling sales
12 Dec 2022 //
REUTERS
Clovis` Rubraca Receives Approval in Europe
08 Dec 2022 //
EMA
Loan default, Rubraca move inches Clovis closer to bankruptcy
06 Dec 2022 //
FIERCEPHARMA
After GSK, FDA asks Clovis to restrict PARP drug`s cancer use
18 Nov 2022 //
FIERCEPHARMA
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca
27 Oct 2022 //
BUSINESSWIRE
Clovis trots out Rubraca prostate cancer partial win
04 Oct 2022 //
FIERCEPHARMA
Clovis Oncology Submits Applications for Rubraca Label Expansion
13 Sep 2022 //
BUSINESSWIRE
Clovis Oncology’s Rubraca Improves Progression-Free Survival in Women
11 Sep 2022 //
BUSINESSWIRE
Clovis needs cash now to stem looming financial challenges
08 Aug 2022 //
FIERCEBIOTECH
Clovis Oncology Announces Second Quarter 2022 Operating Results
08 Aug 2022 //
BUSINESS WIRE
Clovis pulls Rubraca in 3L ovarian cancer amid death risk fears
18 Jun 2022 //
FIERCEPHARMA
Clovis Oncology’s Rubraca as 1L Maintenance Treatment in Ovarian Cancer
06 Jun 2022 //
BUSINESSWIRE
Clovis Oncology Highlights Rubraca and FAP-2286 Data to be Presented at ASCO
28 Apr 2022 //
BUSINESSWIRE
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca at AACR
08 Apr 2022 //
BUSINESSWIRE
Clovis Oncology’s Rubraca Improves Progression-Free Survival in Ovarian Cancer
31 Mar 2022 //
BUSINESSWIRE
Yale Study Finds New Drug Combination Shows Clinical Activity for Patients
19 Sep 2021 //
YALE MEDICINE
Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free
19 Mar 2021 //
BUSINESSWIRE
Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly
21 Dec 2020 //
BUSINESSWIRE
Talazoparib in breast cancer: hint of considerable added benefit
01 Sep 2020 //
IQWIG
FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib)
26 Aug 2020 //
BUSINESSWIRE
Journal of Clinical Oncology Publishes Data from Clovis Oncology’s Rubraca®
17 Aug 2020 //
BUSINESSWIRE
Journal of Clinical Oncology Publishes Additional Data from Clovis Rubraca®
17 Aug 2020 //
BUSINESSWIRE
Clovis Oncology to Highlight Rubraca®& Lucitanib Non-Clinical Data at the AACR
17 Jun 2020 //
BUSINESSWIRE
Clovis Oncology Announces Completion of Target in the ATHENA Trial, a Ph3
10 Jun 2020 //
PRESS RELEASE
Clovis Oncology Announces New Recommendations For Rubraca® (Rucaparib)
28 May 2020 //
PRESS RELEASE
Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib)
28 May 2020 //
BUSINESSWIRE
Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program
21 May 2020 //
BUSINESSWIRE
Clovis Oncology`s Rubraca gets FDA approval for prostate cancer
16 May 2020 //
REUTERS
ProLynx announces Phase 1B clinical trial of its DNA-damaging agent PLX038
13 Apr 2020 //
GLOBENEWSWIRE
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer
17 Jan 2020 //
PM LIVE
Will Clovis’ Rubraca sales shortfall revive talk of a buyout at JP Morgan?
08 Jan 2020 //
FIERCE PHARMA
Will Clovis’ Rubraca sales shortfall revive talk of a buyout at JP Morgan?
08 Jan 2020 //
FIERCE PHARMA
Will Clovis’ Rubraca sales shortfall revive talk of a buyout at JP Morgan?
07 Jan 2020 //
FIERCE PHARMA
GSK, AZ-Merck PARP data heap pressure on Clovis: analysts
02 Oct 2019 //
FIERCE PHARMA
A long-suffering Clovis makes a leap into radiopharmaceuticals, paying $12M
24 Sep 2019 //
ENDPTS
NICE reject Clovis Oncology`s ovarian cancer drug Rubraca
06 Aug 2019 //
PHARMAFILE
Clovis investors bail as Rubraca struggles against Big Pharma
03 Aug 2019 //
FIERCE PHARMA
GSK`s Zejula racks up first-line maintenance win in ovarian cancer
16 Jul 2019 //
FIERCE PHARMA
GSK wins speedy FDA Zejula review in ovarian cancer niche
25 Jun 2019 //
FIERCE PHARMA
Clovis abandons solo Rubraca`s phase 2 test in bladder cancer
15 Apr 2019 //
FIERCE PHARMA
Clovis shutters PhII Rubraca study after data monitors turn thumbs down
12 Apr 2019 //
ENDPTS
Clovis Oncology`s Rubraca shows promise in multiple pancreatic tumour mutations
03 Apr 2019 //
PHARMAFILE
Clovis Oncology Announces Interim Results from Rubraca® (rucaparib)
02 Apr 2019 //
BUSINESSWIRE
Sagard Healthcare & Newcastle UK Announce Monetization Cancer Drug, Rubraca
01 Apr 2019 //
BIOSPACE
Rubraca gets EU approval
26 Jan 2019 //
PHARMA TIMES
No bidding war for Loxo, so did Lilly overpay?
19 Jan 2019 //
FIERCE PHARMA
Clovis CEO to potential bidders: Step right up
11 Jan 2019 //
FIERCE PHARMA
First-line ovarian approval cements AZ’s Lynparza lead
20 Dec 2018 //
PM LIVE
Meeting highlights from the CHMP 10-13 December 2018
14 Dec 2018 //
Will Clovis be the next PARP maker to get swallowed up?
08 Dec 2018 //
FIERCE PHARMA
GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca
04 Dec 2018 //
XCONOMY
AstraZeneca`s Lynparza shown to put brakes on ovarian cancer
23 Oct 2018 //
REUTERS
Clovis loses Servier pact, agrees to settle SEC case
02 Aug 2018 //
FIERCE BIOTECH
